Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Novo Nordisk's oral semaglutide (Ozempic/Wegovy ingredient) failed to slow memory or cognitive decline in 2 Phase 3 Alzheimer disease trials.

Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...

GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...

There are still good reasons to invest in the stock at current levels.

Scientists are testing whether GLP-1 drugs can help to cut cravings for cigarettes, alcohol and opioids — as well as food.

Natco rode Revlimid to multi-year highs, but that one-time opportunity is tapering fast. With earnings set to plunge and ...

The rapid rise of GLP-1 weight loss drugs such as semaglutide and tirzepatide has created two parallel markets. One market consists of ...

A pile of pills and a measuring tape illustrate rising demand for weight-loss medications amid increasing reports of misuse ...

While the WHO study saw reports of suicidal thoughts were slightly higher for semaglutide in particular, the warning applies ...

A new oral GLP-1 receptor agonist, orforglipron, is revolutionizing weight management by offering a needle-free alternative ...